周五盘前，Adaptive Biotechnologies Corp（ADPT）股价大涨11.41%，投资者对公司最新发布的第一季度财报反应积极。这家生物技术公司的业绩表现超出了华尔街分析师的预期，展现了强劲的增长势头。
根据公司公布的财报，截至2025年3月31日的第一季度，Adaptive Biotechnologies调整后每股亏损为0.20美元，明显优于分析师平均预期的0.29美元亏损。公司营收达到5244万美元，同比增长25.2%，同样超过了市场预期的4268万美元。这一业绩显示公司在控制成本的同时，成功实现了收入的大幅增长。
尽管公司仍处于亏损状态，但亏损幅度的显著收窄让投资者看到了公司向盈利迈进的希望。分析师对Adaptive Biotechnologies保持乐观态度，目前平均评级为"买入"，其中7个为"强烈买入"或"买入"，1个为"持有"，没有"卖出"或"强烈卖出"评级。华尔街给予该公司未来12个月的目标价中位数为10.00美元。值得注意的是，Adaptive Biotechnologies今年以来的股价已上涨22.8%，显示出投资者对公司前景的信心。这份亮眼的财报无疑将进一步提振市场情绪，推动股价走高。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.